**Table S2. Clinico-pathological Characteristics of Patients.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **MA (n=21)** | **nMA (n=24)** | **P-value** |
| **Gender** |  |  |  |
| Female  | 8 | 8 | 0.739 |
| Male  | 13 | 16 |  |
| **Age (years)a** | 65 (59.25-69.25) | 66 (52.5-68) | 0.707 |
| **BMIa** | 25.39 (23.31-26.73) | 22.3 (20.21-24.34) | 0.005\* |
| **Synchronous adenoma** |  |  |  |
| Yes | 15 | 10 | 0.045\* |
| No | 6 | 14 |  |
| **Bowel** **obstructiond** |  |  |  |
| Yes | 3 | 4 | 0.826 |
| No | 18 | 20 |  |
| **Hematochezia** |  |  |  |
| Yes | 8 | 13 | 0.281 |
| No | 13 | 11 |  |
| **Tumor sizeac** | 4 (4-5) | 4 (3-5) | 0.602 |
| **Tumor locationb** |  |  |  |
| Left hemi-colon | 2 | 4 | 0.770 |
| Right hemi-colon | 8 | 8 |  |
| Rectum | 11 | 12 |  |
| **CEAa** | 3.07 (1.67-11.94) | 5 (3.25-12.74) | 0.195 |
| **CA 19-9a** | 11.8 (7.79-29.28) | 15.23 (8.15-35.775) | 0.682 |
| **Adjuvant therapy** |  |  |  |
| Yes | 14 | 15 | 0.771 |
| No | 7 | 9 |  |
| **TNM-Stage** |  |  |  |
| I | 2 | 1 | 0.95 |
| IIA | 9 | 14 |  |
| IIIA | 1 | 0 |  |
| IIIB | 9 | 7 |  |
| IIIC | 0 | 2 |  |

\*P<0.05, different from controls by Wilcoxon rank-sum test or Chi-squared test for continuous or categorical variables, respectively.

a Data shown as median (1st and 3rd quartile).

bTumor location: splenic flexure, descending, sigmoid, rectosigmoid were classified as left hemi-colon; ileocecal, ascending, hepatic flexure, transverse were classified as right hemi-colon.

cTumor size defination: maximum diameter.

dBowel obstruction was defined when coloscopy cannot pass through the tumor obstruction.

CEA: carcinoembryonic antigen.

CA19-9: carbohydrate antigen 19-9.